Refine
Language
- English (14)
Is part of the Bibliography
- yes (14) (remove)
Keywords
- Antibody generation (2)
- Assay systems (2)
- cells (2)
- efficient (2)
- endothelial cells (2)
- gene delivery (2)
- immunogenicity (2)
- lipoplexes (2)
- mediated delivery (2)
- pathways (2)
- polarization (2)
- sirna transfection (2)
- therapeutics (2)
- Ageing (1)
- FAK-MAPK (1)
- Ki67 (1)
- Mesenchymal stem cells (1)
- Molecular (1)
- Packaging (1)
- Protein (1)
- beta-galactosidase (1)
- bioinspired materials (1)
- bioinstructive implants (1)
- biological membrane (1)
- biomaterial (1)
- bioprinting (1)
- cell cycle inhibitors (1)
- co-expression (1)
- cyclic olefin copolymer (1)
- endothelial basement membrane (1)
- engineering (1)
- in vitro synthesized mRNA (1)
- in vitro thrombogenicity testing (1)
- integrated co-transfection (1)
- microstructure (1)
- migration (1)
- p16 (1)
- p21 (1)
- parallel co-transfection (1)
- platelets (1)
- poly(tetrafluoroethylene) (1)
- population doubling time (1)
- precondition (1)
- senescence-associated (1)
- successive (1)
- tissue (1)
- transfection (1)
- transfection methods (1)
- vascular grafts (1)
Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.